Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
MELBOURNE, Australia and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 28, 2024 Category: Pharmaceuticals Source Type: clinical trials
Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects
Conditions: Pharmacokinetics Interventions: Drug: MG-K10 humanized monoclonal antibody injection (prefilled syringe); Drug: MG-K10 humanized monoclonal antibody injection （Penicillin bottle） Sponsors: Shanghai Mabgeek Biotech.Co.Ltd; The Second Hospital of Anhui Medical University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Conditions: Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma Interventions: Drug: Metabolically Armed CD19 CAR-T cells Sponsors: Anhui Provincial Hospital; Leman Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Conditions: Leiomyosarcoma; Liposarcoma; Synovial Sarcoma; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma; Epithelioid Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Fibrosarcoma; Pleomorphic Rhabdomyosarcoma; Endometrial Stromal Sarcoma; Desmoplastic Small Round Cell Tumor Interventions: Biological: MASCT-I; Drug: Doxorubicin; Drug: Ifosfamide Sponsors: HRYZ Biotech Co. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Effectiveness of a Nasal Spray on Viral Respiratory Infections
Conditions: Acute Respiratory Tract Infection; Flu, Human; COVID-19; Common Cold Interventions: Device: Nasal Spray HSV Treatment Sponsors: CEN Biotech; Urgo Research, Innovation& Development Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
Conditions: Human Papillomavirus Associated Intraepithelial Neoplasia; Cervical Intraepithelial Neoplasia Grade 2/3; Human Papillomavirus Type 16 Infection; Human Papillomavirus Type 18 Infection Interventions: Biological: RG002 injection Sponsors: RinuaGene Biotechnology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia
TORONTO& SAN FRANCISCO–(BUSINESS WIRE) February 20, 2024–Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Conditions: Idiopathic Pulmonary Fibrosis Interventions: Drug: SV001; Drug: Placebo Sponsors: Shanghai Synvida Biotechnology Co.,Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension
Conditions: Hypertension Interventions: Dietary Supplement: Low dose; Dietary Supplement: High dose; Dietary Supplement: Placebo Sponsors: Universitat de Lleida; Pharmactive Biotech Products S.L.U Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
Conditions: Chronic Hepatitis B Interventions: Drug: GST-HG131; Drug: Placebo to match GST-HG131 Sponsors: Fujian Akeylink Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine
Conditions: Cervical Cancer Interventions: Diagnostic Test: Collect HPV DNA from urine Sponsors: WomenX Biotech Limited; Hong Kong Science and Technology Parks Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye
Conditions: Dry Eye Syndromes Interventions: Device: Carragelose Sponsors: Marinomed Biotech AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
Conditions: Cervical Cancer; CIN Interventions: Device: Special sanitary pad Sponsors: WomenX Biotech Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Conditions: Solid Tumor; HNSCC; RCC; CRC Interventions: Biological: SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody Sponsors: SparX Biotech(Jiangsu) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Conditions: Type2 Diabetes Mellitus Interventions: Drug: Exendin-4 Fc fusion protein injection(1.2mg ）; Drug: Exendin-4 Fc fusion protein injection（2.4mg）; Drug: Dulaglutide; Drug: Metformin Sponsors: Beijing Dongfang Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
